Advertisement
Screener

Vaxart, Inc. (VXRT) Cash and Cash Equivalents, Period Increase (Decrease)

2.0 / 5 stars · 35/87 Roast Me

Vaxart, Inc. Cash and Cash Equivalents, Period Increase (Decrease)

Vaxart, Inc. (VXRT) reported Cash and Cash Equivalents, Period Increase (Decrease) of $9.94 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-06.

Discontinued › Cash Flow › Change in Cash

us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-06

  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$6.42M, a 165.47% decline year-over-year.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$6.00M, a 415.74% decline year-over-year.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $6.43M.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $15.92M.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $9.94M.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$6.83M.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$32.00M, a 740.00% decline from fiscal 2016.
  • Vaxart, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $5.00M.
Period endCash and Cash Equivalents, Period Increase (Decrease) 3 monthCash and Cash Equivalents, Period Increase (Decrease) 6 monthCash and Cash Equivalents, Period Increase (Decrease) 6 month as first filedCash and Cash Equivalents, Period Increase (Decrease) 9 monthCash and Cash Equivalents, Period Increase (Decrease) 9 month as first filedCash and Cash Equivalents, Period Increase (Decrease) 12 month
2018-12-31-$6.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06
-$12.41M
derived: sum of 2 quarters · filed 2019-02-06
-$5.99M
derived: sum of 3 quarters · filed 2019-02-06
$9.94M
10-K · filed 2019-02-06
2018-09-30-$6.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
$427.00K
derived: sum of 2 quarters · filed 2018-11-13
$16.35M
10-Q · filed 2018-11-13
$26.15M
derived: sum of 4 quarters · filed 2018-11-13
2018-06-30$6.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10
$22.35M
10-Q · filed 2018-08-10
$32.15M
derived: sum of 3 quarters · filed 2018-08-10
$34.05M
derived: sum of 4 quarters · filed 2018-08-10
2018-03-31$15.92M
10-Q · filed 2018-05-15
$25.72M
derived: sum of 2 quarters · filed 2018-05-15
$27.62M
derived: sum of 3 quarters · filed 2018-05-15
$26.92M
derived: sum of 4 quarters · filed 2018-08-10
2017-12-31$9.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06
$11.70M
10-Q · filed 2018-02-06
$11.00M
derived: sum of 3 quarters · filed 2018-08-10
-$6.83M
10-K · filed 2019-02-06
2017-09-30$1.90M
10-Q · filed 2017-11-07
$1.20M
derived: sum of 2 quarters · filed 2018-08-10
-$6.49M
10-Q · filed 2018-11-13
-$11.72M
derived: sum of 4 quarters · filed 2018-08-10
2017-06-30-$700.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10
-$5.82M
10-Q · filed 2018-08-10
-$13.62M
derived: sum of 3 quarters · filed 2018-08-10
-$32.00M
10-K · filed 2017-09-01
2017-03-31-$5.12M
10-Q · filed 2018-05-15
-$12.92M
derived: sum of 2 quarters · filed 2018-05-15
-$37.90M
10-Q · filed 2017-05-08
$2.38M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31-$7.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06
-$11.60M
10-Q · filed 2018-02-06
$7.50M
derived: sum of 3 quarters · filed 2018-02-06
-$900.00K
derived: sum of 4 quarters · filed 2018-02-06
2016-09-30-$3.80M
10-Q · filed 2017-11-07
$15.30M
derived: sum of 2 quarters · filed 2017-11-07
$6.90M
derived: sum of 3 quarters · filed 2017-11-07
$600.00K
derived: sum of 4 quarters · filed 2017-11-07
2016-06-30$19.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01
$10.70M
derived: sum of 2 quarters · filed 2017-09-01
$4.40M
derived: sum of 3 quarters · filed 2017-09-01
$5.00M
10-K · filed 2017-09-01
2016-03-31-$8.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08
-$14.70M
derived: sum of 2 quarters · filed 2017-05-08
-$14.10M
10-Q · filed 2017-05-08
-$30.70M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31-$6.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06
-$5.70M
10-Q · filed 2017-02-06
-$22.30M
derived: sum of 3 quarters · filed 2017-02-06
-$21.20M
derived: sum of 4 quarters · filed 2017-02-06
2015-09-30$600.00K
10-Q · filed 2016-11-08
-$16.00M
derived: sum of 2 quarters · filed 2016-11-08
-$14.90M
derived: sum of 3 quarters · filed 2016-11-08
-$7.00M
derived: sum of 4 quarters · filed 2016-11-08
2015-06-30-$16.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13
-$15.50M
derived: sum of 2 quarters · filed 2016-09-13
-$7.60M
derived: sum of 3 quarters · filed 2016-09-13
-$29.10M
10-K · filed 2016-09-13
2015-03-31$1.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10
$9.00M
derived: sum of 2 quarters · filed 2016-05-10
-$12.50M
10-Q · filed 2016-05-10
-$11.80M
derived: sum of 4 quarters · filed 2016-09-13
2014-12-31$7.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-08
-$13.60M
10-Q · filed 2016-02-08
-$12.90M
derived: sum of 3 quarters · filed 2016-09-13
$14.50M
derived: sum of 4 quarters · filed 2016-09-13
2014-09-30-$21.50M
10-Q · filed 2015-11-06
-$20.80M
derived: sum of 2 quarters · filed 2016-09-13
$6.60M
derived: sum of 3 quarters · filed 2016-09-13
-$1.80M
derived: sum of 4 quarters · filed 2016-09-13
2014-06-30$700.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13
$28.10M
derived: sum of 2 quarters · filed 2016-09-13
$19.70M
derived: sum of 3 quarters · filed 2016-09-13
$13.40M
10-K · filed 2016-09-13
2014-03-31$27.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-08
$19.00M
derived: sum of 2 quarters · filed 2015-05-08
$12.70M
10-Q · filed 2015-05-08
$14.70M
derived: sum of 4 quarters · filed 2015-09-11
2013-12-31-$8.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06
-$14.70M
10-Q · filed 2015-02-06
-$12.70M
derived: sum of 3 quarters · filed 2015-09-11
-$16.40M
derived: sum of 4 quarters · filed 2015-09-11
2013-09-30-$6.30M
10-Q · filed 2014-11-07
-$4.30M
derived: sum of 2 quarters · filed 2015-09-11
-$8.00M
derived: sum of 3 quarters · filed 2015-09-11
$16.90M
derived: sum of 4 quarters · filed 2015-09-11
2013-06-30$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11
-$1.70M
derived: sum of 2 quarters · filed 2015-09-11
$23.20M
derived: sum of 3 quarters · filed 2015-09-11
$17.80M
10-K · filed 2015-09-11
2013-03-31-$3.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12
$21.20M
derived: sum of 2 quarters · filed 2014-05-12
$15.80M
10-Q · filed 2014-05-12
$15.83M
10-Q · filed 2013-05-10
$13.57M
derived: sum of 4 quarters · filed 2014-05-12
2012-12-31$24.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-10
$19.50M
10-Q · filed 2014-02-10
$19.54M
10-Q · filed 2013-02-11
$17.27M
derived: sum of 3 quarters · filed 2014-02-10
$17.84M
derived: sum of 4 quarters · filed 2014-02-10
2012-09-30-$5.40M
10-Q · filed 2013-11-12
-$7.63M
derived: sum of 2 quarters · filed 2013-11-12
-$27.99M
10-Q · filed 2012-11-08
-$5.70M
derived: sum of 4 quarters · filed 2013-11-12
2012-06-30-$2.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$1.66M
10-Q · filed 2012-08-09
-$299.00K
derived: sum of 3 quarters · filed 2012-08-09
-$17.60M
10-K · filed 2014-09-30
2012-03-31$565.00K
10-Q · filed 2012-05-10
$1.93M
derived: sum of 2 quarters · filed 2012-05-10
-$19.52M
10-Q · filed 2013-05-10
$35.78M
derived: sum of 4 quarters · filed 2012-08-09
2011-12-31$1.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14
-$13.87M
10-Q · filed 2013-02-11
$35.22M
derived: sum of 3 quarters · filed 2012-08-09
$40.75M
10-K · filed 2012-03-14
2011-09-24$6.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02
$33.86M
derived: sum of 2 quarters · filed 2012-08-09
$39.38M
10-Q · filed 2012-11-08
$55.67M
derived: sum of 4 quarters · filed 2012-08-09
2011-06-30-$34.40M
10-K · filed 2013-09-27
2011-06-25$27.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$33.05M
10-Q · filed 2012-08-09
$49.34M
derived: sum of 3 quarters · filed 2012-08-09
$54.16M
derived: sum of 4 quarters · filed 2012-08-09
2011-03-26$5.53M
10-Q · filed 2012-05-10
$21.81M
derived: sum of 2 quarters · filed 2012-05-10
$26.64M
derived: sum of 3 quarters · filed 2012-05-10
2010-12-25$16.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14
$21.11M
derived: sum of 2 quarters · filed 2012-03-14
-$5.95M
10-K · filed 2012-03-14
2010-09-25$4.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02
-$22.23M
10-Q · filed 2011-11-02
2010-06-26-$27.06M
10-Q · filed 2011-08-03
2009-12-26-$46.93M
10-K · filed 2012-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
EXOZYMES INC. (EXOZ)United States$0.058B